1.23
+0.01999995(+1.65%)
Currency In USD
Address
260 Littlefield Avenue
South San Francisco, CA 94080
United States of America
Phone
650 481 6770
Website
Sector
Healthcare
Industry
Biotechnology
Employees
171
First IPO Date
June 03, 2020
| Name | Title | Pay | Year Born |
| Bernard Coulie | President, Chief Executive Officer & Director | 1.08M | 1966 |
| Keith Lamont Cummings | Chief Financial Officer | 713,074 | 1977 |
| Eric A. Lefebvre | Chief Medical Officer | 762,338 | 1964 |
| Rik Derynck | Scientific Founder & Member of Scientific Advisory Board | 0 | N/A |
| Dean Sheppard | Scientific Founder & Member of Scientific Advisory Board | 0 | N/A |
| Hal Chapman | Scientific Founder & Member of Scientific Advisory Board | 0 | N/A |
| Christopher S. Keenan | Vice President of Investor Relations & Corporate Communications | 0 | N/A |
| Delphine Imbert | Chief Technical Officer | 0 | N/A |
| Lily Cheung | Chief Human Resources Officer | 0 | 1974 |
| Minnie Kuo | Chief Development Officer | 0 | N/A |
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a trials. The company also develops PLN-1474, a small-molecule selective inhibitor of avß1, which completed Phase 1 clinical trial for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis. In addition, it is developing two additional preclinical integrin-based programs, which include an oncology program, as well as a program for an allosteric agonistic monoclonal antibody against an undisclosed integrin receptor for treatment of muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.
